Skip to main content

Table 1 Minimum inhibitory concentrations (MIC90, MIC range [mg/L]) and antimicrobial susceptibility (%S) and resistance (%R) of Gram-positive isolates

From: The Tigecycline Evaluation and Surveillance Trial; assessment of the activity of tigecycline and other selected antibiotics against Gram-positive and Gram-negative pathogens from France collected between 2004 and 2016

Organism/ Antimicrobial

2004–2016

2013–2016

MIC90 (mg/L)

MIC Range (mg/L)

% S

% R

MIC90 (mg/L)

MIC Range (mg/L)

% S

% R

E. faecalis

N = 1429

N = 373

Ampicillina

2

≤0.06 to ≥32

98.4

1.0

1

≤0.06 to ≥32

97.1

2.1

Linezolid

2

≤0.5 to ≥16

99.9

0.1

2

≤0.5 to ≥16

99.7

0.3

Tigecycline

0.25

≤0.008 to 0.5

99.9

0.0

0.12

0.03 to 0.25

100

0.0

Vancomycin

2

0.25 to ≥64

99.2

0.8

2

0.25 to ≥64

99.2

0.8

E. faecalis, VRE

N = 11

N = 3

Amox-clav

≥16

0.25 to ≥16

81.8

18.2

≥16

0.5 to ≥16

[1]

[2]

Ampicillin

≥32

0.5 to ≥32

81.8

18.2

≥32

1 to ≥32

[1]

[2]

Linezolid

2

1 to ≥16

90.9

9.1

≥16

1 to ≥16

[2]

[1]

Tigecycline

0.25

0.06 to 0.25

100

0.0

0.25

0.06 to 0.25

[3]

[0]

E. faecium

N = 537

N = 159

Linezolid

2

≤0.5 to 8

99.8

0.2

2

≤0.5 to 8

99.4

0.6

Tigecycline

0.25

0.015 to 0.25

100

0.0

0.12

0.015 to 0.25

100

0.0

Vancomycin

2

0.25 to ≥64

94.4

5.6

1

0.25 to ≥64

98.1

1.9

E. faecium, VRE

N = 30

N = 3

Linezolid

2

1 to 2

100

0.0

2

1 to 2

[3]

[0]

Tigecycline

0.25

0.03 to 0.25

100

0.0

0.25

0.06 to 0.25

[3]

[0]

S. aureus

N = 3437

N = 947

Levofloxacinb

32

≤0.06 to ≥64

73.2

26.8

16

≤0.06 to ≥64

76.7

23.3

Linezolid

2

≤0.5 to 8

> 99.9

< 0.1

2

≤0.5 to 8

99.9

0.1

Minocyclineb

0.5

≤0.25 to ≥16

95.0

3.0

≤0.25

≤0.25 to ≥16

97.5

2.1

Penicillin

≥16

≤0.06 to ≥16

15.0

85.0

≥16

≤0.06 to ≥16

16.6

83.4

Tigecycline

0.25

≤0.008 to 0.5

100

0.0

0.12

0.015 to 0.5

100

0.0

Vancomycin

1

≤0.12 to 2

100

0.0

1

0.25 to 2

100

0.0

S. aureus, MRSA

N = 953

N = 234

Levofloxacinb

≥64

≤0.06 to ≥64

16.7

83.3

32

0.12 to ≥64

17.5

82.5

Linezolid

2

≤0.5 to 4

100

0.0

4

≤0.5 to 4

100

0.0

Minocyclineb

0.5

≤0.25 to ≥16

94.2

4.6

≤0.25

≤0.25 to 8

95.3

3.8

Penicillin

≥16

0.5 to ≥16

0.0

100

≥16

0.25 to ≥16

0.0

100

Tigecycline

0.25

0.015 to 0.25

100

0.0

0.25

0.015 to 0.5

100

0.0

Vancomycin

1

≤0.12 to 2

100

0.0

1

0.25 to 2

100

0.0

S. agalactiae

N = 1348

N = 378

Levofloxacin

1

≤0.06 to 32

99.1

0.9

1

0.12 to 32

97.9

2.1

Linezolid

1

≤0.5 to 2

100

0.0

1

≤0.5 to 2

100

0.0

Minocycline

≥16

≤0.25 to ≥16

16.1

82.0

≥16

≤0.25 to ≥16

15.6

83.1

Penicillin

0.12

≤0.06 to 0.12

100

0.0

0.12

≤0.06 to 0.12

100

0.0

Tigecycline

0.12

0.015 to 4

99.8

0.1

0.12

0.015 to 4

99.7

0.3

Vancomycin

0.5

≤0.12 to 1

100

0.0

0.5

≤0.12 to 1

100

0.0

S. pneumoniae

N = 1684 (AZM, CLR, CLI, ERY, N = 1500)

N = 496 (AZM, CLR, CLI, ERY, N = 473)

Azithromycinb

≥128

≤0.03 to ≥128

60.5

39.1

≥128

≤0.03 to ≥128

65.8

33.8

Ceftriaxone

1

≤0.03 to 16

80.8

0.5

1

≤0.03 to 2

84.7

0.0

Clarithromycinb

≥128

≤0.015 to ≥128

60.9

38.5

≥128

≤0.015 to ≥128

66.4

32.6

Clindamycinb

≥128

≤0.015 to ≥128

68.5

31.5

≥128

≤0.015 to ≥128

71.9

28.1

Erythromycinb

≥128

≤0.015 to ≥128

60.6

38.7

≥128

≤0.015 to ≥128

66.4

33.2

Levofloxacin

1

≤0.06 to ≥64

99.7

0.3

1

≤0.06 to 2

100

0.0

Linezolid

1

≤0.5 to 4

99.9

0.0

1

≤0.5 to 2

100

0.0

Meropenem (N = 1557) c

0.5

≤0.12 to ≥32

99.8

0.2

1

≤0.12 to 8

99.8

0.2

Minocyclineb (N = 1683)

8

≤0.25 to ≥16

52.4

38.6

8

≤0.25 to ≥16

61.7

31.9

Penicillin

2

≤0.06 to ≥16

53.0

3.0

2

≤0.06 to 8

53.4

2.8

Tigecycline

0.06

≤0.008 to 0.5

–

–

0.03

≤0.008 to 0.06

–

–

Vancomycin

0.5

≤0.12 to 1

100

0.0

0.5

≤0.12 to 1

100

0.0

S. pneumoniae, PRSP

N = 51 (AZM, CLR, CLI, ERY, N = 48)

N = 14 (AZM, CLR, CLI, ERY, N = 14)

Azithromycin

≥128

≤0.03 to ≥128

22.9

77.1

≥128

0.06 to ≥128

38.5

61.5

Ceftriaxone

2

≤0.03 to 8

9.8

9.8

2

≤0.03 to 2

21.4

0

Clarithromycin

≥128

≤0.015 to ≥128

22.9

77.1

≥128

≤0.015 to ≥128

38.5

61.5

Clindamycin

≥128

≤0.015 to ≥128

37.5

62.5

≥128

0.03 to ≥128

46.2

53.8

Erythromycin

≥128

≤0.015 to ≥128

22.9

75.0

≥128

0.03 to ≥128

38.5

61.5

Levofloxacin

1

0.25 to 16

98.0

2.0

1

0.5 to 1

100

0.0

Linezolid

1

≤0.5 to 2

100

0.0

1

≤0.5 to 2

100

0.0

Meropenemc

2

≤0.12 to ≥32

94.1

5.9

2

≤0.12 to 8

92.9

7.1

Minocycline

≥16

≤0.25 to ≥16

19.6

70.6

8

≤0.25 to ≥16

21.4

64.3

Tigecycline

0.03

0.015 to 0.12

–

–

0.03

0.015 to 0.03

–

–

Vancomycin

0.5

0.25 to 1

100

0.0

0.5

025 to 1

100

0.0

  1. a indicates statistically significant decrease in susceptibility (p < 0.01) from 2004 to 2016
  2. b indicates statistically significant increase in susceptibility (p < 0.01) from 2004 to 2016
  3. c Meropenem was introduced to the testing panel in 2006, replacing imipenem; N values of activity against organisms collected from 2006 to 2016 are given
  4. Amox-clav, amoxicillin-clavulanic acid, AZM, azithromycin, CLR, clarithromycin, CLI, clindamycin, ERY, erythromycin, MIC, minimum inhibitory concentration, MIC90, minimum inhibitory concentration required to inhibit growth of 90% of isolates (mg/L), MRSA, methicillin-resistant S. aureus, Pip-taz, piperacillin-tazobactam, PRSP, Penicillin-resistant S. pneumoniae, R, resistant, S, susceptible, VRE, vancomycin-resistant enterococci
Back to article page

Antimicrobial Resistance & Infection Control

ISSN: 2047-2994

Contact us